Description
LIMPA 5/10 mg is a fixed-dose combination oral antidiabetic medication designed to improve glycemic control in adults with type 2 diabetes mellitus. It contains Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Together, these agents work synergistically to reduce blood glucose levels through complementary mechanisms—promoting urinary glucose excretion and enhancing the body’s natural insulin secretion.
LIMPA 5/10 mg is recommended as an adjunct to diet and exercise, and may also be used in combination with other antidiabetic agents when appropriate.
.webp)
.jpeg)
.webp)
.webp)
.jpeg)
 4ML.jpg)
 1000 MG.jpg)
Change Language